This is the doc I found after the fact ... the one I was still looking for I first saw referenced the day the "Omicron" variant was first reported which I believe was Sunday. There was a lady from San Diego appearing on the Lindell extravaganza along with another woman discussing COVID ... she showed the specific place in the Phase 1 trials submission to FDA. But this is what I rather found and posted:
https://clinicaltrials.gov/ct2/show/NCT04368728 Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
Recruitment Status : Recruiting
First Posted :
April 30, 2020 Last Update Posted : October 27, 2021
Sponsor: BioNTech SE
Collaborator: Pfizer
Information provided by (Responsible Party): BioNTech SE
The assessment of boostability will be further expanded in a subset of Phase 3 participants at selected sites in the US who will receive a third dose of BNT162b2 at 30 µg or a third and potentially a fourth dose of prototype BNT162b2VOC at 30 µg (BNT162b2s01, based upon
the South African variant and hereafter referred to as BNT162b2SA). A further subset of Phase 3 participants will receive a third, lower, dose of BNT162b2 at 5 or 10 µg.